Copenhagen, Denmark, 18 January 2023 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies has appointed John Stewart as Senior Vice President of Global Product Supply from 1 January 2023.
John returns to Xellia from LEO Pharma where he was Vice President of Biologics & External Manufacturing. From 2009 to 2013 John was Xellia’s Copenhagen Site Leader. In total he has over 25 years of pharmaceutical experience at organizations such as GSK, Ascendis Pharma, Centrient Pharmaceuticals and most recently LEO Pharma.
John will be part of Xellia’s leadership team and will be based at the Company’s headquarters in Copenhagen, Denmark. He will bring with him and leverage his extensive experience in managing multi-site manufacturing networks and external manufacturing partners in both Active Pharmaceutical Ingredient and Aseptic Drug Product manufacturing technologies.
Carl-Åke Carlsson, CEO and President at Xellia Pharmaceuticals, commented:
“We welcome John back to the Xellia team. He brings a strong track record in managing pharmaceutical manufacturing and his experience in anti-infective production will be invaluable.”
John graduated as a Chemical Engineer from the University of Paisley in the UK and will be based at the Group’s Copenhagen headquarters.
Download as PDF
For more information, please contact:
Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
+45 32 64 55 00
Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Rozi Morris
+44 (0) 20 7457 2020
xellia@instinctif.com